Our laboratory investigates growth factor signaling regulation in normal and tumor cells. We exploit the selectivity of small molecule inhibitors, along with genetic (shRNA, CRISPR), biochemical and proteasome-directed degradation (PROTACs) approaches to interrogate the complexity of signaling networks that promote transformation, tumor maintenance and drug resistance. Our goal is to gain a deeper understanding of oncogenic signaling and use this knowledge to develop mechanism-based therapeutic pharmacologic strategies in cancer.